PRAMEF2

Across TCGA pan-cancer cohorts, PRAMEF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRAMEF2 data layer compared with 13 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PRAMEF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRAMEF2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and COAD are the cancer types where PRAMEF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.659	0.935	.004	32	view →
PDAC	OS	Median	All	0.997	0.781	.001	31	view →
COAD	DFS	Tertile	IV	0.432	0.944	.038	12	view →
LUAD	OS	Tertile	II,III,IV	0.882	0.397	.006	4	view →
LSCC	OS	Median	III,IV	0.897	0.517	.037	3	view →
HNSC	DFS	Median	II,III,IV	0.985	0.894	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRAMEF2–CCRCC (DFS)

Open the CCRCC breakdown →